Terms: = Kidney tumors AND STIL, SIL, 6491, ENSG00000123473, Q15468 AND Treatment
32 results:
1. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma.
Haanen JBAG; Larkin J; Choueiri TK; Albiges L; Rini BI; Atkins MB; Schmidinger M; Penkov K; Michelon E; Wang J; Mariani M; di Pietro A; Motzer RJ
ESMO Open; 2023 Jun; 8(3):101210. PubMed ID: 37104931
[TBL] [Abstract] [Full Text] [Related]
2. [Spontaneous Tumor Lysis Syndrome in a Patient with Testicular Malignant Lymphoma : A Case Report].
Ichikawa K; Momose H; Mizobuchi SI; Itami Y; Nakahama T; Matsumoto Y; Nakamura T
Hinyokika Kiyo; 2019 Feb; 65(2):49-53. PubMed ID: 31067843
[TBL] [Abstract] [Full Text] [Related]
3. IL-15/sil-15Rα gene transfer suppresses Lewis lung cancer growth in the lungs, liver and kidneys.
Sun H; Liu D
Cancer Gene Ther; 2016; 23(2-3):54-60. PubMed ID: 26742578
[TBL] [Abstract] [Full Text] [Related]
4. Interleukin-6 as an emerging regulator of renal cell cancer.
Kamińska K; Czarnecka AM; Escudier B; Lian F; Szczylik C
Urol Oncol; 2015 Nov; 33(11):476-85. PubMed ID: 26296264
[TBL] [Abstract] [Full Text] [Related]
5. Human Renal Normal, Tumoral, and Cancer Stem Cells Express Membrane-Bound Interleukin-15 Isoforms Displaying Different Functions.
Azzi S; Gallerne C; Romei C; Le Coz V; Gangemi R; Khawam K; Devocelle A; Gu Y; Bruno S; Ferrini S; Chouaib S; Eid P; Azzarone B; Giron-Michel J
Neoplasia; 2015 Jun; 17(6):509-17. PubMed ID: 26152359
[TBL] [Abstract] [Full Text] [Related]
6. [Case of peritubular capillary dominant intravascular large B-cell lymphoma (PTC dominant IVLBCL) successfully treated with chemotherapy].
Kado H; Hatta T; Ueno R; Takagi A; Segawa H; Sawada K; Hosokawa Y
Nihon Jinzo Gakkai Shi; 2011; 53(7):1046-52. PubMed ID: 22073871
[TBL] [Abstract] [Full Text] [Related]
7. Human papilloma virus infection and cervical intraepithelial neoplasia in transplanted patients.
Paternoster DM; Cester M; Resente C; Pascoli I; Nanhorngue K; Marchini F; Boccagni P; Cillo U; Ribaldone R; Amoruso E; Cocca N; Cuccolo V; Bertolino M; Surico N; Stratta P
Transplant Proc; 2008; 40(6):1877-80. PubMed ID: 18675077
[TBL] [Abstract] [Full Text] [Related]
8. Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review.
Bien E; Balcerska A
Biomarkers; 2008 Feb; 13(1):1-26. PubMed ID: 17906988
[TBL] [Abstract] [Full Text] [Related]
9. Serum level of soluble interleukin-2 receptor alpha correlates with the clinical course and activity of Wilms' tumour and soft tissue sarcomas in children.
Bien E; Balcerska A; Kuchta G
Biomarkers; 2007; 12(2):203-13. PubMed ID: 17536769
[TBL] [Abstract] [Full Text] [Related]
10. [Usefulness of serum markers in renal cell carcinoma].
Rubio Briones J; Iborra Juan I; Aznar E; Climent MA; López-Guerrero JA; Maíquez J; Monrós Lliso JL; Casanova Ramón-Borja J; Dumont Martínez R; Ricós Torrent JV; Solsona Narbón E
Actas Urol Esp; 2004 May; 28(5):381-6. PubMed ID: 15264681
[TBL] [Abstract] [Full Text] [Related]
11. Pretreatment with interleukin-2 modulates perioperative immunodysfunction in patients with renal cell carcinoma.
Böhm M; Ittenson A; Klatte T; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
Folia Biol (Praha); 2003; 49(2):63-8. PubMed ID: 12779014
[TBL] [Abstract] [Full Text] [Related]
12. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy.
Capuron L; Ravaud A; Gualde N; Bosmans E; Dantzer R; Maes M; Neveu PJ
Psychoneuroendocrinology; 2001 Nov; 26(8):797-808. PubMed ID: 11585680
[TBL] [Abstract] [Full Text] [Related]
13. Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer.
Pavone L; Andrulli S; Santi R; Majori M; Buzio C
Cancer Immunol Immunother; 2001 Apr; 50(2):82-6. PubMed ID: 11401029
[TBL] [Abstract] [Full Text] [Related]
14. Relation of prenephrectomy CD profiles and serum cytokines to the disease outcome and response to IFN-alpha/IL-2 therapy in renal cell carcinoma patients.
Lauerová L; Dusek L; Spurny V; Simicková M; Rovny A; Rejthar A; Kocák I; Kovarík J
Oncol Rep; 2001; 8(3):685-92. PubMed ID: 11295103
[TBL] [Abstract] [Full Text] [Related]
15. [Serum soluble interleukin-2 receptor levels in patients with renal cell carcinoma: a comparison of values before and after surgery].
Tsukamoto S; Ishikawa S; Yamauchi A; Saitou S
Hinyokika Kiyo; 2000 Oct; 46(10):695-9. PubMed ID: 11215193
[TBL] [Abstract] [Full Text] [Related]
16. Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients.
Lissoni P; Rovelli F; Giani L; Fumagalli L; Mandalà M
Nat Immun; 1998; 16(5-6):178-84. PubMed ID: 11061586
[TBL] [Abstract] [Full Text] [Related]
17. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
[TBL] [Abstract] [Full Text] [Related]
18. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy.
Lauerová L; Dusek L; Simícková M; Rovný F; Spurný V; Rovný A; Slampa P; Zaloudík J; Rejthar A; Wotke J; Kovarík J
Neoplasma; 1999; 46(3):141-9. PubMed ID: 10613588
[TBL] [Abstract] [Full Text] [Related]
19. Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application.
Kirchner GI; Franzke A; Buer J; Beil W; Probst-Kepper M; Wittke F; Overmann K; Lassmann S; Hoffmann R; Kirchner H; Ganser A; Atzpodien J
Br J Clin Pharmacol; 1998 Jul; 46(1):5-10. PubMed ID: 9690943
[TBL] [Abstract] [Full Text] [Related]
20. IL-6 is a survival prognostic factor in renal cell carcinoma.
Thiounn N; Pages F; Flam T; Tartour E; Mosseri V; Zerbib M; Beuzeboc P; Deneux L; Fridman WH; Debré B
Immunol Lett; 1997 Jul; 58(2):121-4. PubMed ID: 9271323
[TBL] [Abstract] [Full Text] [Related]
[Next]
